



ORAL PRESENTATION

Open Access

Gene-based treatment options for Usher type 1C by translational read-through of a nonsense mutation

U Wolfrum^{1,2*}, T Goldmann², N Overlack², F Möller², V Belakov³, T Baasov³, K Nagel-Wolfrum²*From* First International Cilia in Development and Disease Scientific Conference (2012)
London, UK. 16-18 May 2012

The Usher syndrome (USH) is the most frequent cause of inherited combined deaf-blindness. The ciliopathy is clinically and genetically heterogeneous, assigned to three clinical USH types of which the most severe type is USH1. The *USH1C* gene encodes the PDZ containing scaffold protein harmonin which is expressed in form of numerous alternatively spliced variants. Harmonin binds directly to all USH1/2 proteins and is a key organizer of USH protein networks in photoreceptor cells. So far no effective treatment for the ophthalmic component of USH exists. Translational read-through was introduced as an innovative therapy option for several non-ocular diseases caused by nonsense mutations leading to a premature termination stop. Here we compare the potential of translational read-through inducing drugs (TRIDs), namely PTC124 (currently in clinical phase-II for non-ocular diseases) as well as the designer aminoglycoside NB30 and NB54 as a treatment option for patients carrying a nonsense mutation in the *USH1C* gene causing USH1. We examined read-through in cell culture, retinal cultures and in vivo in murine retinas. Restoration of the harmonin function was tested by GST pull-downs and actin filament bundling. The TRIDs recovered functional harmonin protein and showed an excellent biocompatibility in retinal cultures with read-through vs. toxicity evidently superior for NB54 and PTC124. In vivo administration of NB54 and PTC124 to mice induced recovery of full-length harmonin. The high biocompatibility combined with the sustained read-through efficacies of these novel drugs emphasizes the potential of TRIDs in treating nonsense mutations in USH as well as in other ciliopathies.

Author details¹Johannes Gutenberg University of Mainz, Germany. ²Cell & Matrix Biology, Institute of Zoology, Johannes Gutenberg University of Mainz, Germany.³Edith and Joseph Fischer Enzyme Inhibitors Laboratory, Schulich Faculty of Chemistry, Technion-Israel Institute of Technology, Israel.

Published: 16 November 2012

doi:10.1186/2046-2530-1-S1-O31

Cite this article as: Wolfrum *et al.*: Gene-based treatment options for Usher type 1C by translational read-through of a nonsense mutation. *Cilia* 2012 **1**(Suppl 1):O31.**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit* Correspondence: wolfrum@uni-mainz.de¹Johannes Gutenberg University of Mainz, Germany

Full list of author information is available at the end of the article

